But the company, in a meeting on Tuesday in Washington with some of its critics, did not say how much the price would be lowered. In an interview with an H.I.V. activist this week, however, Martin Shkreli, the former hedge fund manager who founded and runs Turing, said the reduction would be on the order of 10 percent, an amount not likely to mollify many people. “Since acquiring Daraprim three months ago, our top priority has been to ensure that patients who need Daraprim have ready, affordable access to it,” the company said in a letter given to the groups...